Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-21, Stock:PFE, The news for the past five days is as follows:
2018-09-14: NEWS1: Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know.NEWS2: Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know.NEWS3: Wall Street Analysts Are Mostly Positive on Merck in September.NEWS4: Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know.NEWS5: Week Ahead In Pharmaceuticals: 7 Stocks To Watch (CMRX, VRNA, NITE...).NEWS6: Week Ahead In Pharmaceuticals: 7 Stocks To Watch (CMRX, VRNA, NITE...).NEWS7: How Spark Therapeutics Is Positioned in 2018.NEWS8: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS9: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS10: Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus.NEWS11: Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus.NEWS12: Pharma Stock Roundup: AZN&apos;s Leukemia Drug Wins FDA Nod, MRK&apos;s Keytruda in Focus.NEWS13: Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal.NEWS14: Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal.NEWS15: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS16: Pre-Market Most Active for Sep 14, 2018 :  NIO, NI, CRON, AAPL, TLRY, SHPG, AZN, CGC, ABB, PFE, QQQ, MU.NEWS17: Pre-Market Most Active for Sep 14, 2018 :  NIO, NI, CRON, AAPL, TLRY, SHPG, AZN, CGC, ABB, PFE, QQQ, MU.NEWS18: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.NEWS19: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.NEWS20: Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal.NEWS21: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.NEWS22: ViiV Files Application To EMA For Two-drug Regimen To Treat HIV - Quick Facts.NEWS23: ViiV Files Application To EMA For Two-drug Regimen To Treat HIV - Quick Facts.
2018-09-17: NEWS1: Pfizer&apos;s Skin Disease Candidates Positive in Mid-Stage Study.NEWS2: A Look at the Market Caps of the Pharma Stocks under Review.NEWS3: How Pharmaceutical ETFs Have Performed in 2018.NEWS4: USMV, ONLN: Big ETF Inflows.NEWS5: USMV, ONLN: Big ETF Inflows.NEWS6: These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018.NEWS7: This cancer-fighting biotech sped from startup to IPO filing in 10 months.NEWS8: Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond.NEWS9: Atomwise Enters Evaluation Agreement With Pfizer - Quick Facts.NEWS10: Atomwise Enters Evaluation Agreement With Pfizer - Quick Facts.
2018-09-18: NEWS1: Health care ETF surges toward record in a broad sector rally.NEWS2: New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting.NEWS3: A Review of Pharma Stocks’ EPS Growth Rates.NEWS4: Watson Health Still the Key Driver for IBM’s AI Business.NEWS5: Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts.NEWS6: Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?.NEWS7: Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?.NEWS8: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS9: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS10: Exploring Pharmaceutical Stocks’ Revenue Growth Rates.NEWS11: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS12: Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?.NEWS13: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS14: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS15: A Look at the Dividends Paid by Pharma Stocks in 2018.NEWS16: Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio.NEWS17: Pfizer Reports Addl Analyses From Tafamidis Phase 3 ATTR-ACT Study.NEWS18: Pfizer Reports Addl Analyses From Tafamidis Phase 3 ATTR-ACT Study.NEWS19: Cronos Gets Bigger As It Partners With Ginkgo Bioworks.NEWS20: Pharma Companies Avoid $3.8 Bln In Tax Per Year, Says Oxfam.NEWS21: Pharma Companies Avoid $3.8 Bln In Tax Per Year, Says Oxfam.NEWS22: Pfizer's Skin Disease Candidates Positive in Mid-Stage Study.NEWS23: Pfizer's Skin Disease Candidates Positive in Mid-Stage Study.NEWS24: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.NEWS25: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.
2018-09-19: NEWS1: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS2: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS3: Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates.NEWS4: Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Pfizer.NEWS5: Pharma Stocks in Review: A Valuation Comparison.
2018-09-20: NEWS1: [$$] Companies Stockpile Drugs, Chocolate as They Brace for ‘Hard’ Brexit.NEWS2: Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?.NEWS3: Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?.NEWS4: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS5: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS6: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS7: Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?.NEWS8: Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates.NEWS9: Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates.NEWS10: Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older.NEWS11: Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates.NEWS12: [$$] Companies' Brexit Challenge: Preparing for the Unknown.NEWS13: Pfizer: PF-06482077 Receives Breakthrough Therapy Designation - Quick Facts.NEWS14: Pfizer: PF-06482077 Receives Breakthrough Therapy Designation - Quick Facts.NEWS15: D-Day Nearing For Antares Pharma.NEWS16: D-Day Nearing For Antares Pharma.

Answer: Rise